Suppr超能文献

新型流场流分离药物释放/传递分析法研究脂质体载体中难溶性药物的损失机制和动力学。

Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay.

机构信息

University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark.

Aker Biomarine Antarctic AS, Oksenøyveien 10, P.O Box 496, NO-1327 Lysaker, Norway; Institute for Energy Technology, Isotope laboratories, Instituttveien 18, P.O. Box 40, NO-2027 Kjeller, Norway.

出版信息

J Control Release. 2016 Jun 28;232:228-37. doi: 10.1016/j.jconrel.2016.04.031. Epub 2016 Apr 23.

Abstract

Liposomes represent a versatile drug formulation approach e.g. for improving the water-solubility of poorly soluble drugs but also to achieve drug targeting and controlled release. For the latter applications it is essential that the drug remains associated with the liposomal carrier during transit in the vascular bed. A range of in vitro test methods has been suggested over the years for prediction of the release of drug from liposomal carriers. The majority of these fail to give a realistic prediction for poorly water-soluble drugs due to the intrinsic tendency of such compounds to remain associated with liposome bilayers even upon extensive dilution. Upon i.v. injection, in contrast, rapid drug loss often occurs due to drug transfer from the liposomal carriers to endogenous lipophilic sinks such as lipoproteins, plasma proteins or membranes of red blood cells and endothelial cells. Here we report on the application of a recently introduced in vitro predictive drug transfer assay based on incubation of the liposomal drug carrier with large multilamellar liposomes, the latter serving as a biomimetic model sink, using flow field-flow fractionation as a tool to separate the two types of liposomes. By quantifying the amount of drug remaining associated with the liposomal drug carrier as well as that transferred to the acceptor liposomes at distinct times of incubation, both the kinetics of drug transfer and release to the water phase could be established for the model drug p-THPP (5,10,15,20-tetrakis(4-hydroxyphenyl)21H,23H-porphine). p-THPP is structurally similar to temoporfin, a photosensitizer which is under clinical evaluation in a liposomal formulation. Mechanistic insights were gained by varying the donor-to-acceptor lipid mass ratio, size and lamellarity of the liposomes. Drug transfer kinetics from one liposome to another was found rate determining as compared to redistribution from the outermost to the inner concentric bilayers, such that the overall process could be adequately described by a single 1st order kinetic model. By varying the donor-to-acceptor lipid mass ratio in the range 1:1 to 1:10, a correlation was established between donor-to-acceptor-lipid mass ratio and transfer kinetics, which is regarded essential for scaling to physiological lipid mass ratios. By applying the assay to a series of structurally related model compounds of different bilayer affinity, transfer and release kinetics were established over the whole expected range of liposome bilayer associated drugs in terms of water solubility and lipophilicity. A very rapid transfer and considerable release from liposomes to the water phase was observed for the more water-soluble compounds Sudan II (clogP 5.45) and Sudan III (clogP 6.83). For the more lipophilic compounds, the rate of transfer from the donor liposomes followed the rank order Sudan IV (fastest)>Oil Red O>Sudan Black>p-THPP (slowest). For an equimolar donor-to-acceptor lipid mass ratio, half-lifes of transfer in the range of 12min (Sudan IV) up to 1.5h (p-THPP) were determined. In essence, the results presented here allow for both, mechanistic insights and predictions of drug loss from liposomal carriers upon exposure to biological sinks, which appear more realistic than the commonly employed in vitro release tests.

摘要

脂质体是一种多功能的药物制剂方法,例如可以提高水溶性差的药物的水溶性,还可以实现药物靶向和控制释放。对于后者的应用,药物在血管床中的转运过程中与脂质体载体保持结合至关重要。多年来,已经提出了一系列体外测试方法来预测药物从脂质体载体中的释放。这些方法中的大多数由于这些化合物与脂质体双层的内在结合倾向,即使在广泛稀释的情况下也无法对水溶性差的药物进行现实的预测。相比之下,静脉注射后,由于药物从脂质体载体转移到内源性亲脂性陷窝(如脂蛋白、血浆蛋白或红细胞和内皮细胞的膜),药物往往会迅速丢失。在这里,我们报告了一种新的体外预测药物转移测定法的应用,该方法基于将脂质体药物载体与大多层脂质体孵育,后者用作仿生模型陷窝,使用流场流分离作为分离两种类型脂质体的工具。通过定量在孵育的不同时间与脂质体药物载体结合的药物量以及转移到接受脂质体的药物量,可以建立模型药物 p-THPP(5,10,15,20-四(4-羟苯基)21H,23H-卟啉)的药物转移和释放到水相的动力学。p-THPP 的结构与正在临床评估的脂质体制剂中的光敏剂 Temoporfin 相似。通过改变供体-受体脂质的质量比、脂质体的大小和层状结构,可以获得有关转移机制的深入了解。与从最外层向内同心双层重新分布相比,从一个脂质体到另一个脂质体的药物转移动力学是决定因素,因此整个过程可以通过单个一级动力学模型进行充分描述。通过将供体-受体脂质的质量比在 1:1 至 1:10 的范围内变化,建立了供体-受体-脂质质量比与转移动力学之间的相关性,这被认为对于与生理脂质质量比的缩放至关重要。通过将该测定法应用于一系列结构相关的不同双层亲和力的模型化合物,建立了在水溶性和疏水性方面与脂质体双层相关的整个预期药物的转移和释放动力学范围。对于更水溶性的化合物苏丹 II(clogP 5.45)和苏丹 III(clogP 6.83),观察到从脂质体到水相非常快速的转移和相当大的释放。对于更亲脂性的化合物,从供体脂质体的转移速率遵循苏丹 IV(最快)>油红 O>苏丹黑>p-THPP(最慢)的顺序。对于等摩尔供体-受体脂质质量比,转移的半衰期范围为 12min(苏丹 IV)至 1.5h(p-THPP)。从本质上讲,这里呈现的结果既允许对脂质体载体暴露于生物陷窝时药物损失的机制有深入的了解,也允许进行预测,这比常用的体外释放测试更现实。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验